Home > Boards > US OTC > Medical - Drugs > RegeneRx Biopharmaceuticals Inc (RGRX)

Hey guys,

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Saltlyfe Member Profile
 
Followed By 0
Posts 16
Boards Moderated 0
Alias Born 06/06/10
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/20/2020 5:19:24 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/20/2020 5:16:43 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/20/2020 5:16:05 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/16/2020 4:18:12 PM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 10/16/2020 4:17:12 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/13/2020 7:01:05 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 8/18/2020 6:06:31 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/14/2020 4:05:25 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2020 6:20:13 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2020 6:18:12 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2020 6:16:06 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2020 6:13:49 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2020 6:12:08 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2020 6:10:22 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/15/2020 9:47:02 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 3/30/2020 3:41:50 PM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 3/30/2020 3:40:44 PM
Annual Report (10-k) Edgar (US Regulatory) - 3/20/2020 4:46:25 PM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 11/19/2019 6:01:20 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 11/19/2019 6:01:19 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/14/2019 4:06:54 PM
Saltlyfe   Thursday, 05/14/20 12:42:24 PM
Re: The Night Stalker post# 257
Post # of 309 

Hey guys,

I consider our news today as a positive but it looks like the
only other drug approved for NK was 72 percent successful in
healing. See part of an article I copied below.

However , this proves that TB4 is a healing agent and this bodes
well for the Dry Eye trial that is under way. I would think that
any big pharmaceuticals that have had an eye out here would
be very happy with the results of this trial.

Now we wait for the completion of the Arise 3 to finish. We
we’re looking at a May finish till Covid 19 came around but
maybe we get results by the end of summer fingers crossed.

I think I will add some more here while the price is still cheap.
We have a winner here IMO.

See what the competition did below.

Have a great day !




Published: Aug 23, 2018



- Oxervate is the first-ever application of a human nerve growth factor as drug or treatment, and is the first-ever topical biologic medication approved in ophthalmology.
- The first treatment specifically indicated for neurotrophic keratitis (NK), Oxervate has a mechanism of action that targets the root pathology of the disease.
- Oxervate has the potential to resolve the rare and progressive eye disease with one eight-week cycle of treatment; in clinical trials, approximately 72 percent of patients who used Oxervate achieved complete corneal healing after eight weeks of treatment, and of these patients, approximately 80 percent remained healed after one year.
- Oxervate was authorized by the European Medicines Agency (EMA) in 2017 and represents Dompé's first approved therapy in the United States, where Oxervate received Orphan Drug Designation, Fast Track Status, and Breakthrough Therapy Designation, which led to Priority Review.

MILAN and SAN BRUNO, Calif., Aug. 22, 2018 /PRNewswire/ -- Dompé today announced that the U.S. Food and Drug Administration (FDA) has approved OxervateTM (cenegermin-bkbj ophthalmic solution), a breakthrough therapy for neurotrophic keratitis (NK), a rare and progressive eye disease that can lead to corneal scarring and vision loss.1


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences